The company received formal notification from AEMPS for an extension to its licence 6458E: Manufacturer of Investigational Medicinal Products, to include the manufacture of monodispersed controlled release microcapsules,
People in France, the Netherlands, Spain, Sweden, Switzerland and UK can now take part in the study, which aims to develop tests to identify early signs of Alzheimer’s
Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, will expand its manufacturing operations in Wilson County, Governor
The application seeks to broaden the existing marketing authorisation to include daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed
Hemogenyx will leverage the experience of researchers at the University of Oxford in administering certain biologics to stem cells to attempt to accelerate and improve the engraftment of
Key points from the advice are: The application can be submitted as a hybrid application (under article 10(3) of Directive 2001/83/EC), bridging to the well-established safety and efficacy
As a result of the merger, Can-Fite’s ownership of OphthaliX, immediately post-merger, became approximately 8% of the outstanding shares. As part of the merger, Can-Fite cancelled OphthaliX’s prior
The companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals and its franchise of commercial medications led by Poly-Vi-Flor® (multivitamin
Under the terms of the deal, the CUE Biologics platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets for the treatment of
IONIS-JBI2-2.5Rx is designed to locally reduce the production of an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease. Jansen will now
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.